MARKET

APTO

APTO

Aptose Bioscienc
NASDAQ
1.895
-0.005
-0.26%
Opening 12:19 02/27 EST
OPEN
1.920
PREV CLOSE
1.900
HIGH
1.940
LOW
1.850
VOLUME
53.06K
TURNOVER
0
52 WEEK HIGH
10.13
52 WEEK LOW
1.692
MARKET CAP
29.76M
P/E (TTM)
-0.2408
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at APTO last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at APTO last week (0212-0216)?
Weekly Report · 02/19 10:12
Weekly Report: what happened at APTO last week (0205-0209)?
Weekly Report · 02/12 10:06
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
NASDAQ · 02/05 15:24
Weekly Report: what happened at APTO last week (0129-0202)?
Weekly Report · 02/05 10:11
Piper Sandler Maintains Overweight on Aptose Biosciences, Lowers Price Target to $5-Report Released on 31 January 2024
Benzinga · 02/01 20:09
Aptose Biosciences Announces Regulation FD Disclosure Event
TipRanks · 02/01 09:28
Weekly Report: what happened at APTO last week (0122-0126)?
Weekly Report · 01/29 10:05
More
About APTO
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.

Webull offers Aptose Biosciences Inc stock information, including NASDAQ: APTO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APTO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APTO stock methods without spending real money on the virtual paper trading platform.